CO2018002472A2 - Compuesto de tetrahidrooxepinopiridina - Google Patents
Compuesto de tetrahidrooxepinopiridinaInfo
- Publication number
- CO2018002472A2 CO2018002472A2 CONC2018/0002472A CO2018002472A CO2018002472A2 CO 2018002472 A2 CO2018002472 A2 CO 2018002472A2 CO 2018002472 A CO2018002472 A CO 2018002472A CO 2018002472 A2 CO2018002472 A2 CO 2018002472A2
- Authority
- CO
- Colombia
- Prior art keywords
- compound
- receptor
- activity
- pam activity
- tetrahydroxyepinopyridine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Problema. Se proporciona un compuesto que tiene una actividad moduladora alostérica positiva (actividad PAM) sobre un receptor de acetilcolina nicotínico α7 (receptor α7 nACh). Medios para la solución. Los presentes inventores han estudiado acerca de una actividad PAM sobre un receptor α7 nACh, y han hallado que un compuesto de tetrahidrooxepinopiridina tiene una actividad PAM sobre un receptor α7 nACh, de modo de completar la presente invención. El compuesto de tetrahidrooxepinopiridina de la presente invención tiene una actividad PAM sobre un receptor α7 nACh, y puede esperarse que sea útil como un agente para la prevención o el tratamiento de demencia, deterioro cognitivo, esquizofrenia, enfermedad de Alzheimer, CIAS, síntomas negativos de esquizofrenia, enfermedades inflamatorias o dolor.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015162320 | 2015-08-19 | ||
PCT/JP2016/074145 WO2017030171A1 (ja) | 2015-08-19 | 2016-08-18 | テトラヒドロオキセピノピリジン化合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2018002472A2 true CO2018002472A2 (es) | 2018-05-31 |
Family
ID=58052257
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2018/0002472A CO2018002472A2 (es) | 2015-08-19 | 2018-03-06 | Compuesto de tetrahidrooxepinopiridina |
Country Status (21)
Country | Link |
---|---|
US (1) | US9670219B2 (es) |
EP (1) | EP3345909B1 (es) |
JP (1) | JP6787320B2 (es) |
KR (1) | KR102614279B1 (es) |
CN (1) | CN107922426B (es) |
AR (1) | AR105738A1 (es) |
AU (1) | AU2016308406A1 (es) |
CA (1) | CA2995554C (es) |
CO (1) | CO2018002472A2 (es) |
EA (1) | EA034794B1 (es) |
ES (1) | ES2812246T3 (es) |
HK (1) | HK1251574A1 (es) |
IL (1) | IL257450A (es) |
MX (1) | MX2018002118A (es) |
PH (1) | PH12018500297A1 (es) |
PL (1) | PL3345909T3 (es) |
PT (1) | PT3345909T (es) |
SG (1) | SG11201801193QA (es) |
TW (1) | TW201722962A (es) |
WO (1) | WO2017030171A1 (es) |
ZA (1) | ZA201801098B (es) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010020672A1 (en) * | 2008-08-21 | 2010-02-25 | Neurosearch A/S | Novel phenyl-quinoline-carboxylic acid pyridine derivatives useful as modulators of nicotinic acetylcholine receptors |
GB201106829D0 (en) | 2011-04-21 | 2011-06-01 | Proximagen Ltd | Heterocyclic compounds |
UA109803C2 (xx) | 2011-02-25 | 2015-10-12 | (ПІРИДИН-4-ІЛ)БЕНЗИЛАМІДИ ЯК АЛОСТЕРИЧНІ МОДУЛЯТОРИ АЛЬФА-7 nAChR | |
AR086791A1 (es) * | 2011-07-01 | 2014-01-22 | Lundbeck & Co As H | Moduladores alostericos positivos del receptor de acetilcolina nicotinico |
US20130005743A1 (en) * | 2011-07-01 | 2013-01-03 | H. Lundbeck A/S | New positive allosteric modulators of nicotinic acetylcholine receptor |
-
2016
- 2016-08-18 CN CN201680048575.8A patent/CN107922426B/zh active Active
- 2016-08-18 EA EA201890514A patent/EA034794B1/ru not_active IP Right Cessation
- 2016-08-18 SG SG11201801193QA patent/SG11201801193QA/en unknown
- 2016-08-18 CA CA2995554A patent/CA2995554C/en active Active
- 2016-08-18 PT PT168371607T patent/PT3345909T/pt unknown
- 2016-08-18 AU AU2016308406A patent/AU2016308406A1/en not_active Abandoned
- 2016-08-18 WO PCT/JP2016/074145 patent/WO2017030171A1/ja active Application Filing
- 2016-08-18 JP JP2017535563A patent/JP6787320B2/ja active Active
- 2016-08-18 ES ES16837160T patent/ES2812246T3/es active Active
- 2016-08-18 AR ARP160102537A patent/AR105738A1/es unknown
- 2016-08-18 MX MX2018002118A patent/MX2018002118A/es active IP Right Grant
- 2016-08-18 TW TW105126427A patent/TW201722962A/zh unknown
- 2016-08-18 PL PL16837160T patent/PL3345909T3/pl unknown
- 2016-08-18 KR KR1020187004555A patent/KR102614279B1/ko active IP Right Grant
- 2016-08-18 EP EP16837160.7A patent/EP3345909B1/en active Active
- 2016-09-07 US US15/258,241 patent/US9670219B2/en active Active
-
2018
- 2018-02-09 PH PH12018500297A patent/PH12018500297A1/en unknown
- 2018-02-11 IL IL257450A patent/IL257450A/en unknown
- 2018-02-16 ZA ZA2018/01098A patent/ZA201801098B/en unknown
- 2018-03-06 CO CONC2018/0002472A patent/CO2018002472A2/es unknown
- 2018-08-31 HK HK18111189.8A patent/HK1251574A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
EP3345909B1 (en) | 2020-06-17 |
ES2812246T3 (es) | 2021-03-16 |
US9670219B2 (en) | 2017-06-06 |
EP3345909A4 (en) | 2019-04-10 |
AU2016308406A1 (en) | 2018-03-08 |
IL257450A (en) | 2018-04-30 |
US20170050973A1 (en) | 2017-02-23 |
PT3345909T (pt) | 2020-07-29 |
JPWO2017030171A1 (ja) | 2018-06-07 |
ZA201801098B (en) | 2019-04-24 |
WO2017030171A1 (ja) | 2017-02-23 |
CA2995554A1 (en) | 2017-02-23 |
AR105738A1 (es) | 2017-11-01 |
KR20180037983A (ko) | 2018-04-13 |
PH12018500297A1 (en) | 2018-08-13 |
MX2018002118A (es) | 2018-06-18 |
BR112018003171A2 (pt) | 2018-09-25 |
SG11201801193QA (en) | 2018-03-28 |
JP6787320B2 (ja) | 2020-11-18 |
PL3345909T3 (pl) | 2020-10-19 |
EA201890514A1 (ru) | 2018-07-31 |
EA034794B1 (ru) | 2020-03-23 |
CN107922426A (zh) | 2018-04-17 |
CA2995554C (en) | 2023-06-27 |
TW201722962A (zh) | 2017-07-01 |
HK1251574A1 (zh) | 2019-02-01 |
KR102614279B1 (ko) | 2023-12-18 |
EP3345909A1 (en) | 2018-07-11 |
CN107922426B (zh) | 2021-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2019008487A2 (es) | Compuesto de quinazolina | |
DOP2016000286A (es) | Compuesto heterocíclico que contiene nitrógeno | |
MX2018015656A (es) | Compuestos heterociclicos como antibacterianos. | |
ZA201701299B (en) | Glycosidase inhibitors | |
ECSP18002645A (es) | Agentes, usos y métodos para el tratamiento de la sinucleinopatía | |
IN2015DN01156A (es) | ||
EA201792092A1 (ru) | Редактирование генов с использованием tat-индуцируемой crispr-эндонуклеазы | |
MX2017011997A (es) | Carbamatos de piperacina y metodos de preparacion y uso. | |
MX2016013689A (es) | Compuestos 4-amino-imidazoquinolina. | |
MX2018015657A (es) | Compuestos heterociclico como antibacterianos. | |
CL2016002971A1 (es) | Combinación. | |
CL2016002072A1 (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
MX2015016983A (es) | Moduladores del transporte nuclear y usos de los mismos. | |
CR20140537A (es) | Compuesto heterocíclico nitrogenado | |
MX2019005776A (es) | Inhibidores de magl. | |
MX2019005771A (es) | Inhibidores de magl. | |
UY35276A (es) | Nuevos compuestos que inhiben la actividad de Lp-PLA2 | |
EP4249431A3 (en) | Compositions and methods for treating diseases or disorders using extended release nitric oxide releasing solutions | |
MX2016010328A (es) | Tratamiento con halogeno de ataque cardiaco y lesion isquemica. | |
UY36257A (es) | “compuestos de imidazopiridazina”. | |
MX365609B (es) | Composicion para el cuidado bucal y metodo de uso. | |
CL2016002879A1 (es) | Composiciones farmacéuticas para tratar enfermedades infecciosas | |
EA201991175A1 (ru) | Применение в медицине интерферона-лямбда для лечения фиброза | |
CL2016000884A1 (es) | Derivados de piperazina y su uso como medicamento. | |
MY178960A (en) | Hiv treatment formulation of atazanavir and cobicistat |